| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
1,1-Dimethyl-4-phenylpiperazinium iodide targets nicotinic acetylcholine receptors (nAChRs), functioning as a ganglionic blocker and nicotinic receptor agonist. By activating nicotinic receptors in autonomic ganglia, it stimulates the autonomic nervous system. This action has been used in pharmacological research to study ganglionic transmission and autonomic function. It is not used as a therapeutic agent.
|
|---|---|
| ln Vitro |
In vitro, 1,1-Dimethyl-4-phenylpiperazinium iodide acts as a ganglionic blocker and nicotinic receptor agonist. It activates nicotinic acetylcholine receptors in autonomic ganglia and at the neuromuscular junction. Its activity is assessed in cell-based assays measuring calcium flux, membrane depolarization, or receptor binding. It is used as a research tool to study nicotinic receptor function and autonomic pharmacology. However, detailed in vitro activity data are not extensively documented.
|
| ln Vivo |
1,1-Dimethyl-4-phenylpiperazinium iodide is not used for in vivo pharmacological activity assessment as a therapeutic agent. It is a research chemical used to study autonomic nervous system function. The compound may be administered to animals to investigate ganglionic transmission and nicotinic receptor pharmacology. Its effects on blood pressure and other autonomic functions have been studied in pharmacological research.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 1,1-Dimethyl-4-phenylpiperazinium iodide typically involve competitive binding experiments using nicotinic acetylcholine receptors and radiolabeled or fluorescently labeled nicotinic ligands. The compound's binding affinity to nAChRs is assessed, with IC₅₀ or Kd values determined. Assays are conducted in buffered solutions at physiological pH with appropriate receptor preparations.
|
| Cell Assay |
In vitro cell-based assays for 1,1-Dimethyl-4-phenylpiperazinium iodide utilize cell lines expressing nicotinic acetylcholine receptors. Cells are treated with varying concentrations of the compound to assess receptor activation by measuring calcium influx, membrane potential changes, or downstream signaling. Standard cell culture conditions (37°C, 5% CO₂) with appropriate media are employed.
|
| Animal Protocol |
In vivo animal studies with 1,1-Dimethyl-4-phenylpiperazinium iodide typically involve administration to rodents to study autonomic nervous system function. The compound may be administered via intravenous or intraperitoneal routes. Endpoints include measurements of blood pressure, heart rate, and other autonomic responses. These studies are used to investigate ganglionic transmission and nicotinic receptor pharmacology. All procedures must comply with institutional animal care and use guidelines.
|
| ADME/Pharmacokinetics |
1,1-Dimethyl-4-phenylpiperazinium iodide has a molecular weight of 318.20 g/mol and a molecular formula of C₁₂H₁₉IN₂. It is a quaternary ammonium salt and a piperazine derivative. The compound is a ganglionic blocker and nicotinic receptor agonist used in pharmacological research. It is typically stored under standard laboratory conditions.
|
| Toxicity/Toxicokinetics |
1,1-Dimethyl-4-phenylpiperazinium iodide is intended for research use only and is not approved for human therapeutic applications. As a ganglionic blocker, it may have significant cardiovascular effects and should be handled with care. Standard safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment. The compound should be handled in well-ventilated areas with proper waste disposal procedures.
|
| Additional Infomation |
1,1-Dimethyl-4-phenylpiperazine iodide (DMPP) is an N-arylpiperazine compound belonging to the quaternary ammonium salt, piperazine salt, and organoiodide class. It is a nicotine acetylcholine receptor agonist. DMPP is a selective nicotine cholinergic agonist commonly used as a research tool. DMPP activates nicotine receptors in autonomic ganglia but has little effect on the neuromuscular junction.
1,1-Dimethyl-4-phenylpiperazinium iodide (CAS#: 54-77-3) has a molecular formula of C₁₂H₁₉IN₂ and a molecular weight of 318.20 g/mol. It is a ganglionic blocker and nicotinic receptor agonist used in pharmacological research to study autonomic nervous system function. This compound is not a drug and has not undergone clinical trials. |
| Molecular Formula |
C12H19IN2
|
|---|---|
| Molecular Weight |
318.20
|
| Exact Mass |
318.059
|
| CAS # |
54-77-3
|
| PubChem CID |
5911
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
234-238 °C(lit.)
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
15
|
| Complexity |
173
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[I-].[N+]1(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])N(C2C([H])=C([H])C([H])=C([H])C=2[H])C([H])([H])C1([H])[H]
|
| InChi Key |
XFZJGFIKQCCLGK-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C12H19N2.HI/c1-14(2)10-8-13(9-11-14)12-6-4-3-5-7-12;/h3-7H,8-11H2,1-2H3;1H/q+1;/p-1
|
| Chemical Name |
1,1-dimethyl-4-phenylpiperazin-1-ium;iodide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1427 mL | 15.7134 mL | 31.4268 mL | |
| 5 mM | 0.6285 mL | 3.1427 mL | 6.2854 mL | |
| 10 mM | 0.3143 mL | 1.5713 mL | 3.1427 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
